Cassava Sciences INC 8-K filings

Cassava Sciences has reached a settlement with the SEC, agreeing to pay a $40 million penalty to resolve charges related to disclosures about its Phase 2b clinical trial of simufilam.

Cassava Sciences has engaged its former CEO, Remi Barbier, as a consultant for a one-year term, focusing on scientific research and product approvals.

Biotech firm Cassava Sciences has appointed Rick Barry as CEO, signaling a new chapter for the company as it advances its Alzheimer's drug candidate, simufilam, through pivotal Phase 3 trials.

Cassava Sciences has filed an amendment to its previous 8-K report to correct an error in the reported net loss per share for the six months ended June 30, 2024.

Cassava Sciences announced a net income of $6.2 million for Q2 2024, driven by a change in fair value of warrant liabilities, and provided updates on its Phase 3 clinical trials for simufilam.

Cassava Sciences' Executive Chairman, Rick Barry, released an open letter to the community, emphasizing his commitment to the company's mission and outlining the next steps for their Alzheimer's drug development.

Cassava Sciences has reached a settlement in a shareholder derivative lawsuit, resulting in modifications to the CEO's bonus plan and the implementation of corporate governance reforms.

Cassava Sciences has announced the resignation of its CEO, Remi Barbier, and the appointment of Richard Barry as Executive Chairman, alongside other leadership and governance changes.

Cassava Sciences is under investigation by the DOJ and SEC, with a recent indictment of a former collaborator for alleged research fraud, prompting an internal investigation and supplemental disclosures regarding a Phase 2b study.

Cassava Sciences has approved discretionary cash bonuses for its executive officers and amended the employment agreement of its CFO to include a change-in-control clause.

Cassava Sciences held its 2024 Annual Meeting of Stockholders, electing three directors, ratifying the appointment of Ernst & Young LLP as auditor, and approving executive compensation.

Cassava Sciences announced a net income of $25 million for Q1 2024, driven by warrant exercises, and provided updates on their Phase 3 clinical trials for Simufilam in Alzheimer's disease.

Cassava Sciences has successfully raised over $125 million through the exercise of warrants previously distributed to shareholders, resulting in the issuance of approximately 5.7 million common shares.

Cassava Sciences announces the final trading day for its SAVAW warrants on NASDAQ is May 2, 2024, with a final cash-exercise deadline of May 6, 2024.

Cassava Sciences has announced May 6, 2024, as the final day for warrant holders to exercise their warrants, with a nominal redemption to occur on May 7, 2024 for unexercised warrants.

Cassava Sciences reported its full-year 2023 financial results, highlighted by $121.1 million in cash and cash equivalents, and provided updates on its Phase 3 clinical program for simufilam.

Cassava Sciences announced that patients with mild Alzheimer's disease who continuously received simufilam for two years showed no decline in cognitive scores, while those with non-continuous treatment experienced a slight decline.